1型糖尿病中的microRNAs:作用,病理机制和治疗潜力
Hayeong Cho1, Se Eun Ha1, Rajan Singh1
1Department of Physiology & Cell Biology, University of Nevada School of Medicine, Reno, NV 89557, USA.
调节性微RNAs (miRNAs) 是1型糖尿病 (T1D) 发病过程中的关键. 本综述探讨了如何向miRNAs可以提供新的疗法,以恢复胰腺β细胞功能并阻止T1D进展.
科学领域:
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 1型糖尿病 (T1D) 是一种自身免疫性疾病,导致胰腺β细胞破坏和胰岛素缺乏.
- 目前的治疗方法可以控制症状,但不能预防疾病的进展或β细胞的丧失.
- 自免疫过程和慢性炎症驱动T1D中的β细胞破坏.
研究的目的:
- 审查微RNAs (miRNAs) 在1型糖尿病发病过程中的作用.
- 在动物模型和T1D的人类患者中探索miRNA失调.
- 评估针对T1D治疗的向miRNA的治疗潜力.
主要方法:
- 在T1D中对miRNA的研究的文献综述.
- 在糖尿病动物模型中分析miRNA表达特征.
- 检查miRNA参与人类T1D病变的研究.
主要成果:
- 微RNAs (miRNAs) 是T1D中涉及的基因表达的关键调节者.
- 失调的miRNAs与胰腺β细胞的自身免疫破坏有关.
- 在糖尿病动物模型和人类患者中观察到特定的miRNA配置文件.
结论:
- 微RNAs (miRNAs) 代表了T1D的潜在诊断生物标志物.
- 针对失调的miRNAs提供了一个有希望的T1D治疗策略.
- 基于miRNA的疗法可以恢复β细胞功能并减缓疾病的进展.
更多相关视频
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
07:01Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
Published on: May 10, 2022
相关概念视频
MicroRNAs
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Experimental RNAi
